3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
25
Neoplasms
12
Stomach Neoplasms
10
Endometrial Neoplasms
10
Lung Neoplasms
9
Lymphatic Metastasis
7
Melanoma
6
Head and Neck Neoplasms
6
Carcinoma, Hepatocellular
6
Uterine Cervical Neoplasms
5
Rectal Neoplasms
5
Esophageal Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Vulvar Neoplasms
3
Sarcoma
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Colorectal Neoplasms
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Skull Base Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Peritoneal Neoplasms
2
Osteosarcoma
2
Margins of Excision
2
Lymphedema
2
Hypoparathyroidism
2
Giant Cell Tumor of Bone
2
Interventions
padeliporfin
5
Nivolumab
3
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Radiosurgery
2
Cyclophosphamide
2
Cisplatin
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
spartalizumab
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
lutetium Lu 177 dotatate
1
guadecitabine
1
genexol-PM
1
durvalumab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Site
×
Indocyanine Green
×
Clear all
NCT02111824
2021-09-17
MIMIG
The Methodist Hospital Research Institute
Phase 1
Terminated
7 enrolled